EGFR and neoplasm: As we know, the enzyme COX-2 is essential for prostaglandin synthesis, so using a COX-2 inhibitor in combination with BRAF inhibitors (BRAFis) and/or EGFR inhibitors (EGFRis) is an interesting therapeutic strategy that has already shown longer-lasting suppression of tumor growth in patient-derived tumor xenograft models [67].